DaVita Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Javier J. Rodriguez
- Full Time Employees
- 78,000
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 2000 16th Street Denver CO United States of America 80202
- IPO Date
- Oct 31, 1995
- CIK
- 0000927066
- Website
- davita.com
- Similar Companies
- Business
- DaVita Inc. DaVita Inc. provides kidney care services, primarily dialysis treatments for patients with chronic kidney failure and end-stage kidney disease; operates approximately 2,675 outpatient dialysis centers in the United States serving more than 200,000 patients and 367 centers in 11 other countries serving around 49,400 patients; offers related laboratory services, including routine tests for dialysis patients and other physician-prescribed tests; delivers home-based hemodialysis, hospital inpatient dialysis, and acute inpatient dialysis services; provides integrated kidney care and disease management through DaVita Integrated Kidney Care for risk-based arrangements; conducts clinical research via DaVita Clinical Research since 1985 across pharmaceutical and medical device development; supports nephrologists with technology solutions through DaVita Physician Solutions; and develops innovative health care solutions for kidney disease patients through DaVita Venture Group. The company, incorporated in 1994 and formerly known as DaVita HealthCare Partners Inc. until a 2016 name change, maintains world headquarters in Denver, Colorado, and generates the majority of revenues from Medicare and government-based programs while targeting commercial payers for higher margins; it holds a 37% share of the U.S. dialysis market and operates internationally across regions including Latin America, Europe, and Asia. DaVita Inc. recently expanded internationally through 2024 acquisitions from Fresenius Medical Care for $300 million, adding over 270 clinics in Brazil, Colombia, Chile, and Ecuador to become Latin America's largest dialysis provider; entered new markets in Ecuador and Chile while deepening presence in Colombia; refinanced debt with a new $1.9 billion Term Loan B-2 and $3.5 billion credit facilities including a $2 billion Term Loan A-2 and $1.5 billion revolving facility in 2025; issued $1 billion in senior notes due 2033; and reported Q3 2025 revenues of $3.42 billion amid volume challenges from flu season, Hurricane Helene, and a cyber incident.
Is DaVita (DVA) a Great Value Stock Right Now?
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
Dow Extends Record Run With Over 400-Point Pop
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
DaVita Q2 Earnings Call Highlights
DaVita Inc (DVA) (Q2 2026) Earnings Call Highlights: Strong Volume Growth and Strategic Execution Drive Confidence
DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript
DaVita flags lower revenue per treatment, reaffirms annual forecast
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates
Is DaVita Inc (DVA) Overvalued After Q2 Earnings Beat? EPS at $4.02 and Revenue at $3.554 Billion; GF Score: 86/100
DaVita Inc. 2nd Quarter 2026 Results
Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
DaVita: I Believe This Is Overvalued
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
Everyone Is Watching Greg Abel. But Another Berkshire Hathaway Stock Picker Is Quietly Winning in 2026.